CSIMarket
 
Quest Diagnostics Inc  (NYSE: DGX)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 


 DGX $171.9050 $0.5250 0.31%

 Volume (M): 14   Open : 172.91    52 Wk Avg :  157.38


Quest Diagnostics Inc DGX OHLC Open High Low Closing Chart




  What happened with Quest Diagnostics Inc's Stock

Over the course of April 2025, Quest Diagnostics Inc?s stock experienced a dynamic month marked by a blend of upbeat earnings news and intermittent setbacks, ultimately resulting in a 5.49% increase from $168.95 to $178.22. Although the overall market registered a decline of 0.51% during the same period, Quest Diagnostics managed to outperform not only the broader market but also its industry peers and suppliers, some of which were down by up to -3.46% or saw only marginal gains of 0.11%.

In early April, investor sentiment was cautious as news began to flow. On April 1, the company announced the date for its Q1 2025 financial results, which led to a modest rise of 0.05%. This was followed by a dividend announcement on April 2 Quest Diagnostics was set to pay a US$0.80 dividend but the market reacted negatively with a -0.78% drop, perhaps reflecting short-term profit-taking or adjustment to dividend expectations.

Mid-month saw further oscillations. The positive reaction on April 3, where a news angle



During March 2025, Quest Diagnostics Inc (ticker symbol: DGX) experienced a modest decline in its stock price, decreasing by 2.56% from $173.64 at the beginning of the month to $169.20 by the end. Despite this overall downturn, Quest Diagnostics demonstrated resilience and outperformed several key benchmarks and its peers within the industry.

The stock reached its peak at $178.87 on March 10, 2025, indicating investor optimism mid-month. However, this was followed by volatility, culminating in the lowest price of $163 on March 12, 2025. The most significant single-day drop occurred on March 11, with shares falling by 2.87%, reflecting potential market concerns or sector-specific challenges during that period.

Notably, Quest Diagnostics' performance surpassed the broader market, which declined by 5.96% over the same timeframe. This outperformance extended to its suppliers, whose shares fell by 2.61%, slightly more than Quest's 2.56% decrease. Additionally, the Medical Laboratories industry as a whole saw a substantial average decline of 11.37%, further highlighting Quest Diagnostics' relative strength in a struggling sector.

Quest?s best day in March was on March 3, when shares surged by 2.34%, showcasing the company's ability to capitalize on positive market sentiment or favorable company-specific news. Overall, while Quest Diagnostics faced a net decline in stock value, its performance was commendable against both the broader market and its direct competitors, underscoring its stability and investor confidence amidst challenging conditions.

During February 2025, Quest Diagnostics Inc experienced an impressive upward trend in its share price, marking a month of notable recovery and resilience relative to wider market trends. The stock appreciated by 6.83%, moving from an opening level of $161.84 to close at $172.90. Notably, the ascent was not linear; the stock demonstrated volatility along its upward trajectory. Early in the month, on February 3, shares hit a low of $160.01, setting a baseline from which investors would see subsequent gains. Despite experiencing a challenging workday on February 12 with a decline of 1.55%, the company managed to rebound strongly. This recovery was highlighted on February 13, when shares enjoyed a robust day-of-trade gain of 2.66%, indicating strong investor confidence and an overall positive sentiment.

The stock?s momentum culminated near the end of the month as it reached its highest point of $176.44 on February 25, reflecting successful market positioning and effective operational strategies. Against a backdrop of broader market performance where the overall market and the shares in the specific sector dropped by 0.7% and 5.53% respectively Quest Diagnostics not only stood its ground but outperformed these benchmarks. Additionally, the shares significantly outpaced those of its suppliers, whose stocks fell by -2.96% and -5.25% during the same period. This robust performance amidst industry headwinds underscores Quest Diagnostics? strategic advantage and growing investor confidence in its financial future.



In January 2025, Quest Diagnostics Inc. (NYSE: DGX) demonstrated a notable performance, marking a '7.33% increase' in its stock price from '$151.96' to '$163.10'. This upward trajectory signifies a strong start to the year, especially when compared to the broader market, where Quest outperformed by '2.33%'. Despite this positive growth, it?s important to contextualize Quest?s performance relative to its suppliers, where the stock underperformed, although specific metrics regarding the suppliers' performance were not provided.

Throughout the month, Quest Diagnostics showcased volatility, reaching its 'peak price of $167.08' on 'January 30, 2025'. Interestingly, this date was paradoxically reported as both the highest point and the day with the best performance, albeit with a '-1.78%' change, suggesting a possible reporting discrepancy. Conversely, the stock experienced its lowest point at '$148.70' on 'January 16, 2025', highlighting a significant rebound within the month.

Comparatively, the 'Medical Laboratories' industry faced challenges, declining by '-0.53%' on average during the same period. In contrast, portfolios within the broader sector saw an average increase of '3.84%', positioning Quest Diagnostics favorably against industry peers. This resilience amid a struggling industry underscores Quest?s robust operational strategies and investor confidence.

However, internal inconsistencies in daily performance data indicate areas for further scrutiny. Overall, Quest Diagnostics Inc. demonstrated commendable growth in January 2025, navigating market fluctuations effectively and maintaining a competitive edge within its sector.

'Quest Diagnostics Inc's Headwinds Persist Despite Marginal Gains in September 2024'

In September 2024, Quest Diagnostics Inc's stock exhibited only a modest increase of 1.13%, closing the month at $155.25, down from an initial price of $157. This performance is indicative of a struggling stock that is trailing behind the broader market trends. Throughout the month, the shares reached a peak price of $159.36 on September 4, but quickly fell toward a notable low of $149.52 by September 11 a decline that significantly reflects the volatility in the stock performance.

Interestingly, September saw Quest Diagnostics Inc experiencing its most favorable day on September 16 when the shares recorded their best movement, though this was still a negative drop of 1.37%. Conversely, the worst day for the stock also saw a decline of 1.37% on September 20, highlighting the stock's instability during the month. The healthcare sector, on average, gained 0.13% during this period, while the Medical Laboratories industry in which Quest operates faced a decline averaging -0.77%. This broader sector weakness could explain the underperformance of Quest Diagnostics? shares despite the slight overall increase.

Analyzing these trends, it is clear that the stock is navigating through turbulent waters, possibly due to factors such as investor sentiment, economic influences, and changes in the healthcare landscape. While a slight uptick can be seen, the stock?s overall trajectory in September raises concerns for investors about future performance and suggests that further strategic adjustments may be necessary for Quest Diagnostics to regain momentum in a competitive market.

'Analysis of Quest Diagnostics Inc's Stock Performance in July 2024'

In July 2024, Quest Diagnostics Inc exhibited notable fluctuations in its stock performance, culminating in an overall increase of 4.72%, rising from $137.52 at the beginning of the month to $142.3 by the end. However, this upward trajectory was not linear, as the stock experienced a rollercoaster of events. The month started on a low note with shares hitting their bottom at $136.3 on July 1, a price that may have alarmed investors. Following this decline, the stock rebounded and reached its pinnacle of $150.585 on July 17, suggesting a period of positive momentum for the company, likely influenced by favorable market sentiments or strong operational performance.

Noteworthy is the performance decline observed on July 23, where the stock endured its steepest drop of 4.34%. This drop could reflect market corrections or negative developments impacting investor confidence. When comparing Quest Diagnostics' performance against broader market indices, it is evident that the company's shares fared better than the market average, which saw a -0.71% performance during the same month. Moreover, within the specialize Medical Laboratories industry, where stocks rose by an average of 10.67%, Quest Diagnostics demonstrated resilience and competitive strength, showcasing its capability to outperform CSIMarkets index tracking its suppliers over the quarter, which suggest it remains a strong player within its sector.

Overall, while July brought volatility to Quest Diagnostics' stock, the general upward trend over the month represents a positive sign for investors. The stock's performance not only surpassed broader market metrics but also signals a potential for growth amid sector-specific challenges and opportunities.

'Quest Diagnostics Inc: A Fluctuating Month in June 2024 Amidst Broader Market Trends'

In June 2024, Quest Diagnostics Inc experienced a modest increase in its share price, which rose by 2.95%, moving from $135.47 at the beginning of the month to $140.92 by the end. Despite this growth, the performance of Quest Diagnostics shares lagged behind the broader market, indicating that while the company showed some resilience, it did not keep pace with the overall economic landscape. This underperformance was starkly evident as shares in the Medical Laboratories industry averaged a decline of 4.25% during the same period.

The month was notable for its volatility; shares hit a peak of $143.83 on June 6, 2024. However, following this high, a downward trend occurred, with the stock touching its lowest point of $135.47 on June 28, 2024. This fluctuation underscores a challenging market environment, with investors likely reacting to industry-wide pressures and possibly to broader economic indicators. Quest Diagnostics' shares recorded their best single-day performance during this month, although the specifics of that percentage increase remain undisclosed.

In contrast to the struggles seen within the medical laboratory sector, Quest Diagnostics outperformed the CSIMarkets index, which tracks the performance of the company?s suppliers, over the previous quarter. This could indicate that while Quest is facing short-term volatility, its long-term fundamentals remain relatively strong, distinguishing it from its competitors in the sector. Ultimately, June 2024 proved to be a mixed month for Quest Diagnostics Inc, characterized by a modest rise in share price juxtaposed against broader industry declines.





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright � 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com